Ebenezer Care Center | |
2545 Portland Avenue South, Minneapolis, Minnesota 55404 | |
(612) 879-2261 | |
Name | Ebenezer Care Center |
---|---|
Location | 2545 Portland Avenue South, Minneapolis, Minnesota |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 119 |
Occupancy Rate | 80.17% |
Medicare ID (CCN) | 245587 |
Legal Business Name | Ebenezer Society |
Ownership Type | Non Profit - Corporation |
NPI Number | 1184622870 |
Organization Name | EBENEZER SOCIETY |
Doing Business As | EBENEZER CARE CENTER |
Address | 2545 Portland Ave, Minneapolis, MN 55404 |
Phone Number | 612-879-2262 |
News Archive
The MagnaSafe Registry, a new multicenter study led by scientists at The Scripps Research Institute (TSRI), has demonstrated that appropriately screened and monitored patients with standard or non-MRI-conditional pacemakers and defibrillators can undergo MRI at a field strength of 1.5 tesla without harm.
Researchers from the Monell Center and Tokyo University of Agriculture have used a novel molecular method to identify chemical compounds from common foods that activate human bitter taste receptors.
NexMed, Inc, a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the Company has filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) for a Phase II trial of its recently acquired cancer drug candidate PrevOnco™, in combination with doxorubicin in patients with advanced, unresectable hepatocellular carcinoma (HCC). The FDA has 30 days to comment on the IND before NexMed can proceed with human testing.
iCo Therapeutics Inc. today reported financial results for the three months ended September 30, 2009. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP).
› Verified 6 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
The MagnaSafe Registry, a new multicenter study led by scientists at The Scripps Research Institute (TSRI), has demonstrated that appropriately screened and monitored patients with standard or non-MRI-conditional pacemakers and defibrillators can undergo MRI at a field strength of 1.5 tesla without harm.
Researchers from the Monell Center and Tokyo University of Agriculture have used a novel molecular method to identify chemical compounds from common foods that activate human bitter taste receptors.
NexMed, Inc, a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the Company has filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) for a Phase II trial of its recently acquired cancer drug candidate PrevOnco™, in combination with doxorubicin in patients with advanced, unresectable hepatocellular carcinoma (HCC). The FDA has 30 days to comment on the IND before NexMed can proceed with human testing.
iCo Therapeutics Inc. today reported financial results for the three months ended September 30, 2009. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP).
› Verified 6 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 17.65 | 14.46 |
Percentage of long-stay residents who lose too much weight | 8.81 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 66.85 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.97 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 0.56 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 5.86 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 4.72 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 94.72 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 28.87 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 67.44 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 18.94 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 12.58 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 9.02 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 96.98 | 95.98 |
Percentage of short-stay residents who made improvements in function | 82.83 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 77.21 | 82.93 |
News Archive
The MagnaSafe Registry, a new multicenter study led by scientists at The Scripps Research Institute (TSRI), has demonstrated that appropriately screened and monitored patients with standard or non-MRI-conditional pacemakers and defibrillators can undergo MRI at a field strength of 1.5 tesla without harm.
Researchers from the Monell Center and Tokyo University of Agriculture have used a novel molecular method to identify chemical compounds from common foods that activate human bitter taste receptors.
NexMed, Inc, a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the Company has filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) for a Phase II trial of its recently acquired cancer drug candidate PrevOnco™, in combination with doxorubicin in patients with advanced, unresectable hepatocellular carcinoma (HCC). The FDA has 30 days to comment on the IND before NexMed can proceed with human testing.
iCo Therapeutics Inc. today reported financial results for the three months ended September 30, 2009. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP).
› Verified 6 days ago
Walker Methodist Health Center Location: 3737 Bryant Avenue South, Minneapolis, Minnesota 55409 Phone: (612) 827-5931 | |
Mount Olivet Careview Home Location: 5517 Lyndale Avenue South, Minneapolis, Minnesota 55419 Phone: (612) 827-5677 | |
Fairview University Trans Serv Location: 2450 Riverside Avenue South, Minneapolis, Minnesota 55454 Phone: (612) 273-4197 | |
The Villa At Bryn Mawr Location: 275 Penn Avenue North, Minneapolis, Minnesota 55405 Phone: (612) 377-4723 | |
The Estates At Chateau Llc Location: 2106 Second Avenue South, Minneapolis, Minnesota 55404 Phone: (612) 874-1603 | |
Benedictine Health Center Of Minneapolis Location: 618 East 17th Street, Minneapolis, Minnesota 55404 Phone: (612) 879-2800 |